CompletedPhase 2NCT00005964
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Previously Untreated Aggressive Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
Studying Aggressive B-cell non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alliance for Clinical Trials in Oncology
- Principal Investigator
- Andrew Zelenetz, MD, PhDMemorial Sloan Kettering Cancer Center
- Intervention
- filgrastim(biological)
- Enrollment
- 59 enrolled
- Eligibility
- All sexes
- Timeline
- 2000 – 2006
Study locations (30)
- Veterans Affairs Medical Center - Birmingham, Birmingham, Alabama, United States
- University of California San Diego Cancer Center, La Jolla, California, United States
- Veterans Affairs Medical Center - San Francisco, San Francisco, California, United States
- UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States
- CCOP - Christiana Care Health Services, Wilmington, Delaware, United States
- Lombardi Cancer Center, Washington D.C., District of Columbia, United States
- Walter Reed Army Medical Center, Washington D.C., District of Columbia, United States
- CCOP - Mount Sinai Medical Center, Miami Beach, Florida, United States
- Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, United States
- University of Chicago Cancer Research Center, Chicago, Illinois, United States
- Holden Comprehensive Cancer Center at The University of Iowa, Iowa City, Iowa, United States
- Veterans Affairs Medical Center - Togus, Togus, Maine, United States
- Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00005964 on ClinicalTrials.govOther trials for Aggressive B-cell non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT07474051Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical TrialsAvenCell Therapeutics, Inc.
- RECRUITINGEARLY PHASE1NCT07344818An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell LymphomaPeking University People's Hospital
- RECRUITINGPHASE2NCT07097363Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin LymphomaUniversity of Washington
- RECRUITINGPHASE2NCT06649812Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2, PHASE3NCT07168980Chemotherapy With Rituximab for Aggressive B-NHL in Children and AdolescentsChildren's Cancer Group, China
- RECRUITINGPHASE2NCT06996132Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell LymphomaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1, PHASE2NCT06536049Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin LymphomaYazeed Sawalha
- RECRUITINGPHASE2NCT06834373Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell TherapyMayo Clinic